J. Lorenz et al., Treatment outcomes in acute exacerbations of chronic bronchitis: Comparison of macrolides and moxifloxacin from the patient perspective, J INT MED R, 29(2), 2001, pp. 74-86
Citations number
17
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Moxifloxacin, a new respiratory quinolone, was compared with the macrolides
azithromycin, clarithromycin and roxithromycin in a cohort study to assess
clinical, safety and health-related outcomes of these antimicrobials in ge
neral practice settings. In total 332 patients with acute exacerbations of
chronic bronchitis (AECB) each received one of the antimicrobial agents for
a standard short course of therapy. Random allocation of therapeutic agent
s occurred by centre, not individuals, and the drugs were prescribed in an
open manner. In addition to clinical evaluation by their physicians, all pa
tients kept daily diaries to assess AECB symptoms over the study period, th
erapy received and quality of life. The overall clinical response rate was
96% and all four regimens were well tolerated. After 14 days there were no
significant differences between the study groups, but analyses of patients'
daily evaluations of certain AECB specific symptoms showed a faster respon
se rate in the moxifloxacin group.